Arthroscopic “Debridement and Implant Retention” With Local Administration of Exebacase (Lysin CF-301) Frontiers in Medicine, May 2021, Volume 8, Article 550853
Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis The Journal of Clinical Investigation, Volume 130, Issue 7, July 1, 2020
Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography Antimicrobial Agents & Chemotherapy, July 2020, Volume 64, Issue 7
Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against Staphylococcus aureus in a Neutropenic Murine Thigh Infection Model Antimicrobial Agents & Chemotherapy, March 2020, Volume 64, Issue 3
Exebacase Demonstrates In Vitro Synergy with a Broad Range of Antibiotics against both Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Antimicrobial Agents & Chemotherapy, February 2020, Volume 64, Issue 2
Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats Antimicrobial Agents & Chemotherapy, October 2019, Volume 63, Issue 10
Antimicrobial Activity of Exebacase (Lysin CF-301) against the Most Common Causes of Infective Endocarditis Antimicrobial Agents & Chemotherapy, (2019) 63 (10) e01078-19
In vitro activity of Exebacase (CF-301) against clinical Staphylococcus aureus surveillance isolates from the United States, Europe, and Latin America, 2015–2017 Diagnostic Microbiology and Infectious Disease, Volume 95, Issue 4, December 2019, 114879
Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus Antimicrobial Agents & Chemotherapy, (2019) 63 (6) e02616-18
The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant Staphylococcus aureus Bacteriolysis Antimicrobial Agents & Chemotherapy, (2019) 63 (4) e02291-18
In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-Resistant Subsets Presented at ID Week 2021, September 29, 2021
Amurin Peptides: New Direct Lytic Agents (DLAs) with Broad Spectrum Antimicrobial Activity Against Gram-negative (GN) ESKAPE Pathogens Presented at World Microbe, June 2021
Lysin CF-370 Exhibits Broad Spectrum Antimicrobial Activity Against Gram-Negative (GN) ESKAPE Pathogens Presented at World Microbe, June 2021
Lysin CF-370 In Vivo Efficacy Against a Carbapenem-Resistant Pseudomonas aeruginosa in a Rabbit Infective Endocarditis Model Presented at World Microbe, June 2021
PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models Presented at ID Week 2019, October 4, 2019
Exebacase (Lysin CF-301) Activity Against Staphylococcus aureus (S. aureus) Isolates from Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) Presented at ID Week 2019, October 3, 2019
Activity of Exebacase (CF-301) Against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms on Orthopedic Kirschner Wires Presented at ID Week 2019, October 3, 2019
Impact of Dose-Administration Strategies of the Antistaphylococcal Lysin Exebacase, (CF-301), in Addition to Daptomycin (DAP) in an Experimental Infective Endocarditis (IE) Model due to Methicillin-Resistant Staphylococcus aureus (MRSA) Presented at ID Week 2019, October 3, 2019
Amurin Peptide App2-M1 Eradicates Stenotrophomonas maltophilia Biofilms Formed on Hemodialysis Catheters in the Setting of Human Infection Presented at ASM-ESCMID 2019, September 4, 2019
CF-301 and Daptomycin Treatment of Methicillin-Resistant Staphylococcus aureus Associated Experimental Osteomyelitis Presented at ASM 2019, June 23, 2019
